Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RUTI - Archivel Farma

Next Previous
Drug Profile

RUTI - Archivel Farma

Alternative Names: RUTI

Latest Information Update: 03 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Archivel Farma
  • Developer Archivel Farma; London School of Hygiene & Tropical Medicine; RUTI Immunotherapeutics
  • Class Antineoplastics; Cancer vaccines; COVID-19 vaccines; Tuberculosis vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II COVID 2019 infections; Tuberculosis
  • No development reported Allergic rhinitis; Asthma; Bladder cancer

Most Recent Events

  • 03 Aug 2026 Archivel Farma plans a phase-I trial for Bladder cancer in Spain (SC) (CTIS2026-525897-20-00)
  • 13 Feb 2025 Immunogenicity, efficacy, and adverse events data from phase I RUTIVAC-1 trial in Bladder cancer presented at the Genitourinary Cancers Symposium (ASCO-GU-2025)
  • 28 Jan 2025 No recent reports of development identified for phase-I development in Bladder-cancer(Prevention) in Spain (SC, Liposomal)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top